Cartesian Therapeutics (NASDAQ:RNAC) Issues Earnings Results, Misses Estimates By $0.56 EPS

Cartesian Therapeutics (NASDAQ:RNAC) posted its quarterly earnings results on Monday. The company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.56), Zacks reports. The business had revenue of $0.95 million during the quarter, compared to analysts’ expectations of $0.10 million.

Cartesian Therapeutics Trading Down 9.2%

RNAC stock traded down $0.83 during mid-day trading on Tuesday, reaching $8.19. 180,339 shares of the stock traded hands, compared to its average volume of 188,578. Cartesian Therapeutics has a 52-week low of $5.98 and a 52-week high of $18.80. The company has a market cap of $212.94 million, a P/E ratio of -5.25 and a beta of 0.41. The stock’s fifty day moving average is $7.21 and its 200-day moving average is $8.17.

Insiders Place Their Bets

In other Cartesian Therapeutics news, CFO Blaine Davis sold 10,591 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $6.82, for a total value of $72,230.62. Following the completion of the sale, the chief financial officer owned 121,220 shares in the company, valued at $826,720.40. This represents a 8.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 60.30% of the company’s stock.

Hedge Funds Weigh In On Cartesian Therapeutics

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Cartesian Therapeutics by 548.2% in the fourth quarter. Millennium Management LLC now owns 164,366 shares of the company’s stock valued at $1,185,000 after acquiring an additional 139,009 shares during the period. Marshall Wace LLP raised its stake in Cartesian Therapeutics by 110.1% during the 4th quarter. Marshall Wace LLP now owns 178,140 shares of the company’s stock valued at $1,284,000 after purchasing an additional 93,334 shares during the last quarter. Walleye Capital LLC bought a new stake in Cartesian Therapeutics in the 4th quarter valued at $316,000. Renaissance Technologies LLC bought a new stake in Cartesian Therapeutics in the 4th quarter valued at $296,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Cartesian Therapeutics in the 3rd quarter worth $256,000. Institutional investors own 86.95% of the company’s stock.

Cartesian Therapeutics News Roundup

Here are the key news stories impacting Cartesian Therapeutics this week:

• Positive Sentiment: Several brokerages reiterated/upgraded coverage and set substantially higher price targets — Wedbush reaffirmed an “outperform” rating with a $38 target and Needham reiterated a “buy” with a $42 target, both implying large upside versus current levels. Analyst optimism can support buying interest and underpin the rally in RNAC shares. Benzinga
• Positive Sentiment: Cantor Fitzgerald upgraded Cartesian from “neutral” to “overweight” (new $16 price target) — a separate report/summary on the upgrade is available via MSN. Upgrades from institutional research teams often attract momentum buying and increase investor visibility. Cantor Fitzgerald upgrade (MSN)
• Neutral Sentiment: Company issued a full-year 2025 financial report and business update; the filing contains operational and guidance details that investors will parse for pipeline progress and cash runway. The update is a mixed-context item whose impact depends on specific program milestones and guidance. Business Insider
• Neutral Sentiment: Short-interest reporting shows effectively zero reported short interest for early March, though the published figures appear anomalous (NaN/zero), so short-squeeze dynamics are unlikely to be a clear driver based on this data alone.
• Negative Sentiment: Recent quarterly results included a large EPS miss: the company reported ($3.57) EPS vs. consensus (~$0.82 loss), although revenue modestly exceeded expectations. The sizable earnings shortfall increases near-term downside risk as investors reassess cash burn, funding needs, and timeline for clinical progress. Earnings / MarketBeat

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Cantor Fitzgerald upgraded Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price objective on the stock in a report on Monday. Wedbush reissued an “outperform” rating and set a $38.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday. BTIG Research reaffirmed a “buy” rating on shares of Cartesian Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cartesian Therapeutics in a research note on Monday, December 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of Cartesian Therapeutics in a report on Monday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.